Phaseline

Companies › AB Science

AB Science: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 3, 1 Phase 1; Neurology, Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Masitinib
Fibroblast growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor
FGFR3, KIT, PDGFRB, PDGFRAPhase 3Amyotrophic Lateral SclerosisDec 2027
AB8939–Phase 1Acute Myeloid Leukemia RefractoryDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05211570AB8939Phase 1Acute Myeloid Leukemia RefractoryOncologyDec 2026
NCT03127267MasitinibPhase 3Amyotrophic Lateral SclerosisNeurologyDec 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

FGFR3 (1) KIT (1) PDGFRB (1) PDGFRA (1)

Companies with the same targets

AstraZeneca Deciphera Pharmaceuticals Blueprint Medicines Daiichi Sankyo Tyra Biosciences Exelixis Cogent Biosciences Chia Tai Tianqing Pharmaceutical Group Novartis Gossamer Bio USA

Companies built like this

Advenchen Laboratories TransThera Sciences (Nanjing) SK Life Science Luye Pharma Group Cogent Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.